The United Laboratories International Holdings Limited (HK:3933)
:3933
Top Page
The United Laboratories International Holdings
(3933)
Select Model
Select Model
Rating:71Outperform
Price Target:
HK$13.00
▲(10.73% Upside)
Action:ReiteratedDate:11/19/25
The overall score of 71 for HK:3933 is driven primarily by strong financial performance, with exceptional profitability and a stable balance sheet. A compelling valuation with a low P/E ratio and high dividend yield further supports the score. However, bearish technical indicators reflecting downward price momentum significantly weigh on the overall assessment.
Positive Factors
Revenue Growth
Consistent revenue growth indicates strong market demand and effective business strategies, supporting long-term financial stability and expansion.
Negative Factors
Cash Flow Management
Fluctuating cash flow and recent data gaps pose challenges to financial stability, potentially impacting the company's ability to fund operations and growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Consistent revenue growth indicates strong market demand and effective business strategies, supporting long-term financial stability and expansion.
Read all positive factors
The United Laboratories International Holdings (3933) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$20.80B
Dividend Yield5.11%
Average Volume (3M)9.98M
Price to Earnings (P/E)9.7
Beta (1Y)0.75
Revenue Growth0.39%
EPS Growth4.94%
CountryHK
Employees17,000
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.13
Shares Outstanding1,973,026,500
10 Day Avg. Volume7,816,257
30 Day Avg. Volume9,977,158
Financial Highlights & Ratios
PEG Ratio-3.94
Price to Book (P/B)1.47
Price to Sales (P/S)1.53
P/FCF Ratio15.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$16.65Price Target Upside41.85% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.88
Revenue Forecast (FY)HK$12.80B
The United Laboratories International Holdings Business Overview & Revenue Model
Company Description
The United Laboratories International Holdings Limited (3933) is a Hong Kong-based company primarily engaged in the manufacturing and distribution of pharmaceuticals, including generic and branded drugs. The company operates in various sectors suc...
How the Company Makes Money
The United Laboratories generates revenue primarily through the sale of its pharmaceutical products, which includes both generic and branded medications. Key revenue streams are derived from the production and distribution of prescription drugs an...
The United Laboratories International Holdings Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
88
Very Positive
Cash Flow
78
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.10B | 13.76B | 13.74B | 11.33B | 9.70B | 8.77B |
| Gross Profit | 6.66B | 6.08B | 6.33B | 4.97B | 4.21B | 3.81B |
| EBITDA | 3.88B | 3.35B | 3.98B | 2.54B | 1.98B | 1.83B |
| Net Income | 3.06B | 2.66B | 2.70B | 1.58B | 988.10M | 702.99M |
Balance Sheet | ||||||
| Total Assets | 29.43B | 25.83B | 21.02B | 18.98B | 16.33B | 14.96B |
| Cash, Cash Equivalents and Short-Term Investments | 9.01B | 6.33B | 4.26B | 4.74B | 3.33B | 3.00B |
| Total Debt | 5.13B | 3.16B | 1.50B | 2.46B | 1.84B | 2.21B |
| Total Liabilities | 13.82B | 11.40B | 8.27B | 8.37B | 6.99B | 6.35B |
| Stockholders Equity | 15.57B | 14.39B | 12.73B | 10.61B | 9.34B | 8.61B |
Cash Flow | ||||||
| Free Cash Flow | 417.70M | 1.33B | 977.50M | 1.25B | 1.06B | 1.04B |
| Operating Cash Flow | 1.35B | 3.20B | 2.44B | 2.03B | 1.54B | 1.57B |
| Investing Cash Flow | -1.20B | -1.73B | -1.56B | -594.92M | -587.22M | 166.76M |
| Financing Cash Flow | -373.46M | 596.91M | -1.36B | -24.17M | -620.93M | -1.91B |
The United Laboratories International Holdings Technical Analysis
Neutral
11.74
Price Trends
11.82
Negative
12.04
Negative
13.50
Negative
Market Momentum
-0.59
Positive
44.29
Neutral
57.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3933, the sentiment is Neutral. The current price of 11.74 is above the 20-day moving average (MA) of 11.03, below the 50-day MA of 11.82, and below the 200-day MA of 13.50, indicating a bearish trend. The MACD of -0.59 indicates Positive momentum. The RSI at 44.29 is Neutral, neither overbought nor oversold. The STOCH value of 57.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:3933.
The United Laboratories International Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$25.63B | 22.15 | 7.26% | 3.13% | 10.56% | -13.58% | |
72 Outperform | HK$14.03B | 11.34 | 24.04% | 3.93% | 19.05% | 13.68% | |
71 Outperform | HK$20.80B | 9.66 | 12.63% | 5.11% | 0.39% | 4.94% | |
70 Outperform | HK$31.78B | 11.61 | 14.47% | 4.09% | -0.45% | 9.00% | |
63 Neutral | HK$34.96B | 13.02 | 8.60% | 2.26% | 11.78% | 19.06% | |
61 Neutral | HK$39.39B | 6.37 | 7.91% | 2.95% | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:3933
The United Laboratories International Holdings
10.54
-0.25
-2.29%
HK:0867
China Medical System Holdings
14.33
7.38
106.19%
HK:1513
Livzon Pharmaceutical Group
29.20
4.54
18.40%
HK:3320
China Resources Pharmaceutical Group Ltd.
6.27
1.70
37.08%
HK:1681
Consun Pharmaceutical Group Ltd.
17.07
9.04
112.68%
HK:0512
Grand Pharmaceutical Group Limited
7.22
1.88
35.21%
The United Laboratories International Holdings Corporate Events
United Laboratories Gains Approval for Levofloxacin Eye Drops
Dec 9, 2025
The United Laboratories International Holdings Limited announced that its subsidiary, Zhuhai United Laboratories Co., Ltd, has received approval from the China National Medical Products Administration for its Levofloxacin Eye Drops. This approval ...
United Laboratories’ Moxifloxacin Eye Drops Gain Approval, Boosting Ophthalmic Portfolio
Dec 9, 2025
The United Laboratories International Holdings Limited announced that its Moxifloxacin Hydrochloride Eye Drops have received approval from the China National Medical Products Administration. This approval is expected to enhance the company’s...
United Laboratories’ Antibiotic Product Passes Consistency Evaluation
Nov 26, 2025
The United Laboratories International Holdings Limited announced that its product, Cefoperazone Sodium and Sulbactam Sodium for Injection, has passed the consistency evaluation by the China National Medical Products Administration. This approval e...
United Laboratories Announces Vesting of Award Shares
Nov 13, 2025
The United Laboratories International Holdings Limited announced the vesting of 3,369,800 Award Shares to its executives and employees as part of the 2023 Share Award Scheme. This move reflects the company’s commitment to rewarding performan...
United Laboratories Advances TUL01101 Tablets to Phase III Trials
Nov 10, 2025
The United Laboratories International Holdings Limited announced the successful completion of a Phase II clinical trial for its TUL01101 Tablets, a JAK1 inhibitor, in treating moderate-to-severe atopic dermatitis in adults. The trial demonstrated ...
United Laboratories Acquires Award Shares for Share Scheme
Nov 5, 2025
The United Laboratories International Holdings Limited has announced the acquisition of 3,500,000 Award Shares by the Trustee through on-market transactions to fulfill the vesting obligations of the 2023 Share Award Scheme. This move is part of th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.